John Sperzel is the CEO of T2 Biosystems, a company focused on innovative diagnostics for healthcare. He joined T2 in January 2020, taking over from previous CEO John McDonough. Sperzel has a solid background in management, holding a Bachelor's degree...

John Sperzel is the CEO of T2 Biosystems, a company focused on innovative diagnostics for healthcare. He joined T2 in January 2020, taking over from previous CEO John McDonough. Sperzel has a solid background in management, holding a Bachelor's degree in Business Administration from Plymouth State College. Before T2, he led Chembio Diagnostics from 2014 to 2020 and was also the CEO of International Technidyne Corporation. Under his leadership, T2 has pursued aggressive growth and development strategies, striving to bring new technologies to market. In 2023, his compensation amounted to $385,000, including a performance-based bonus. Sperzel's approach is data-driven, aligning team performance with company goals. Since taking charge, he has emphasized the importance of clinical and business development milestones for success, making tough calls when necessary to steer the company forward, indicating his resilience and adaptability in the fast-paced biotech industry.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other T2 Biosystems CEOs

T

John Sperzel

CEO of T2 Biosystems

Education

Bachelor of Science degree in Business Administration/Management from Plymouth State College

Field of Expertise

Business & Management

Sector of Economy

Healthcare

Born

January 1, 1964 - 61 years ago

CEO of T2 Biosystems for

5 years 4 months (Jan 2020 - Present)

Previous Experience

CEO of Chembio Diagnostics, Inc.

Rivals

Competitors/colleagues of John Sperzel

Holdings

See how much did John Sperzel make over time.

As of September 2023, John Sperzel's stock holdings in T2 Biosystems reflect a significant commitment to the company. When he joined in 2020, he received a notable grant of stock options numbering 3 million shares, which vest over four years....

As of September 2023, John Sperzel's stock holdings in T2 Biosystems reflect a significant commitment to the company. When he joined in 2020, he received a notable grant of stock options numbering 3 million shares, which vest over four years. By 2022, he had vested a substantial number of Restricted Stock Units (RSUs), indicating a successful retention of shares in the company. His vested stock amounted to $150,000 in value this year. Notably, fluctuations in the stock price have influenced Sperzel's net worth tied to T2. With the stock trading at various prices over the years, it's clear his faith in the company's direction has been strong, aligning his personal wealth with the company's market performance.

Mar 18, 2025

T

shares

TTOO @ $0.12

Total Stock Sold

$603.10K

TTOO

$603.10K

97.73 TTOO shares

What if they kept their stock?

If John Sperzel didn't sell their stock, today they would have:
Extra TTOO97.73 shares worth $654.79K.
This is 8.57% and $51.69K more than what they got when they sold the stock.

Insider Trading

See recent insider trades of John Sperzel.

TTOO

$6.06K

TTOO at $0.62/share

Feb 20, 2023

Sale

TTOO

$15.00K

TTOO at $0.50/share

Apr 7, 2022

Purchase

Compensation History

See how much did John Sperzel make over time.

In 2023, John Sperzel's total compensation was $385,000, a significant drop from the previous year's $865,500. This included a base salary of $300,000, a performance bonus of $50,000, stock vesting worth $15,000 from previous grants, and other benefits totaling $20,000. The performance metrics for his bonus were centered around strategic goals set by the Board, focusing on revenue growth and operational efficiency. In 2022, his hefty bonus was partly due to strong company performance, showcasing the dynamic nature of CEO compensation in the biotech sector. This compensation structure not only motivates Sperzel but also reflects T2's aim to retain talent and encourage company performance.

Year

2023

Total Compensation

$385.00K

Salary

$300.00K

Board Justification

The compensation philosophy is designed to align executive compensation with company performance, ensuring that pay is competitive with peer companies while also promoting retention and motivation among executives.

Bonus

$50.00K

Board Justification

The bonus is based on the achievement of specific performance metrics set by the Board of Directors for the fiscal year 2023.

Other

$20.00K

Board Justification

Other compensation includes health benefits and retirement contributions paid in 2023.

Restricted Stock

$15.00K(1K Common Stock)

Board Justification

The vested stock consists of 1000 shares of Common Stock that were granted in previous years and vested in 2023.

Performance Metrics

Performance metrics include revenue growth, operational efficiency, and achievement of strategic goals set by the Board.

Other T2 Biosystems CEOs

Here are other CEOs of T2 Biosystems

John McDonough

Ex-CEO of T2 Biosystems

January 2007 - January 2020